# A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation

Source: https://onco.cc/trials/nct06936644/  
OnCo record `nct06936644` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Fulzerasib and Ivonescimab in KRAS G12C-mutant non-small-cell lung cancer, run by Shanghai Chest Hospital, not yet recruiting.

## Summary

A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation is a phase 2 interventional study registered as NCT06936644 by Shanghai Chest Hospital, with 39 participants planned, started 2025-04-30 and due to reach its primary completion in 2027-04-30. Interventions recorded: IBI351+AK112. Conditions recorded: KRAS G12C Lung Cancer.

Linked to the drug Fulzerasib because the registry names it among its interventions and KRAS G12C-mutant non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06936644
- Phase: 2
- Setting: A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
- Sponsor: Shanghai Chest Hospital
- Enrolled: 39

## Sources

- ClinicalTrials.gov NCT06936644: https://clinicaltrials.gov/study/NCT06936644

## Connected records

- cancers: [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/)
- drugs: [Fulzerasib](https://onco.cc/drugs/fulzerasib/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/)

---
JSON: https://onco.cc/api/v1/entities/nct06936644.json